34945.jpg
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
July 29, 2019 07:00 ET | ProQR Therapeutics N.V.
Access based on positive interim analysis of clinical data as well as preclinical data to date  PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at...